<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186133</url>
  </required_header>
  <id_info>
    <org_study_id>2010-035</org_study_id>
    <nct_id>NCT01186133</nct_id>
  </id_info>
  <brief_title>Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice</brief_title>
  <acronym>IRIS-DES</acronym>
  <official_title>Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate effectiveness and safety of the new drug-eluting
      stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the
      &quot;real world&quot; daily practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive patients receiving New DES without a mixture of other DES
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)</measure>
    <time_frame>at 12 months post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>death (all-cause and cardiac)</measure>
    <time_frame>at 12 months and annually up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>at 12 months and annually up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>at 12 months and annually up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-lesion and target-vessel revascularization</measure>
    <time_frame>at 12 months and annually up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedural success</measure>
    <time_frame>at 1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>21</number_of_groups>
  <enrollment type="Anticipated">40000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Percutaneous Transluminal Coronary Angioplasty</condition>
  <arm_group>
    <arm_group_label>DESSIAN</arm_group_label>
    <description>consecutive patients receiving CYPHER stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K-XIENCE</arm_group_label>
    <description>consecutive patients receiving Xience stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GENOUS</arm_group_label>
    <description>consecutive patients receiving GENOUS stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ELEMENT</arm_group_label>
    <description>consecutive patients receiving PROMUS-ELEMENT stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRIME</arm_group_label>
    <description>consecutive patients receiving XIENCE-PRIME stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOBORI</arm_group_label>
    <description>consecutive patients receiving NOBORI stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INTEGRITY</arm_group_label>
    <description>consecutive patients receiving RESOLUTE-INTEGRITY stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XPEDITION</arm_group_label>
    <description>consecutive patients receiving XIENCE-XPEDITION stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIOMATRIX</arm_group_label>
    <description>consecutive patients receiving BIOMATRIX stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CILOTAX</arm_group_label>
    <description>consecutive patients receiving CILOTAX stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEB</arm_group_label>
    <description>consecutive patients receiving Drug eluting balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DESYNE</arm_group_label>
    <description>consecutive patients receiving DESYNE stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREMIER</arm_group_label>
    <description>consecutive patients receiving PROMUS-PREMIER stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORSIRO</arm_group_label>
    <description>consecutive patients receiving ORSIRO stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONYX</arm_group_label>
    <description>consecutive patients receiving ONYX stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BVS</arm_group_label>
    <description>consecutive patients receiving Bioresorbable Vascular Scaffold</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BVS AMI</arm_group_label>
    <description>consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultimaster</arm_group_label>
    <description>consecutive patients receiving Ultimaster stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synergy</arm_group_label>
    <description>consecutive patients receiving Synergy stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biofreedom</arm_group_label>
    <description>consecutive patients receiving Biofreedom stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Firehawk</arm_group_label>
    <description>consecutive patients receiving Firehawk stent</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patients amenable to PCI
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  coronary disease amenable to percutaneous coronary intervention (PCI)

          -  no clinical and lesion limitations

        Exclusion Criteria:

          -  patients with a mixture of several DES

          -  terminal illness with life expectancy less than 1 year

          -  patients with cardiogenic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung-Jung Park, MD</last_name>
    <email>sjpark@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Duk-Woo Park, MD</last_name>
    <email>dwpark@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korean centres</name>
      <address>
        <city>Multiple Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>December 17, 2017</last_update_submitted>
  <last_update_submitted_qc>December 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine</investigator_title>
  </responsible_party>
  <keyword>coronary disease</keyword>
  <keyword>drug eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is not a publicly funded trial.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

